Eyepoint Pharmaceuticals Inc Expected to Post Q3 2019 Earnings of ($0.18) Per Share (EYPT)

Share on StockTwits

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) – Analysts at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for Eyepoint Pharmaceuticals in a research report issued on Tuesday, March 12th. B. Riley analyst A. D’silva now forecasts that the company will earn ($0.18) per share for the quarter, down from their previous estimate of ($0.15). B. Riley also issued estimates for Eyepoint Pharmaceuticals’ Q4 2019 earnings at ($0.09) EPS, Q1 2020 earnings at ($0.09) EPS and Q2 2020 earnings at ($0.08) EPS.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%. The company had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $0.66 million.

A number of other research analysts have also recently weighed in on the stock. ValuEngine upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, February 13th. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research report on Thursday, February 7th. Finally, HC Wainwright set a $5.00 price objective on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, January 4th.

Shares of EYPT opened at $2.47 on Thursday. Eyepoint Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $3.94. The firm has a market capitalization of $233.34 million, a P/E ratio of -4.26 and a beta of 2.01. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.37.

A number of hedge funds have recently bought and sold shares of EYPT. Virtu Financial LLC bought a new position in Eyepoint Pharmaceuticals during the fourth quarter valued at $31,000. Bank of New York Mellon Corp increased its position in Eyepoint Pharmaceuticals by 78.5% during the fourth quarter. Bank of New York Mellon Corp now owns 51,501 shares of the company’s stock valued at $97,000 after acquiring an additional 22,645 shares during the last quarter. Regal Investment Advisors LLC increased its position in Eyepoint Pharmaceuticals by 27.3% during the fourth quarter. Regal Investment Advisors LLC now owns 69,950 shares of the company’s stock valued at $132,000 after acquiring an additional 15,000 shares during the last quarter. Private Advisor Group LLC bought a new position in Eyepoint Pharmaceuticals during the third quarter valued at $134,000. Finally, California Public Employees Retirement System bought a new position in Eyepoint Pharmaceuticals during the second quarter valued at $135,000. Institutional investors and hedge funds own 57.99% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Recommended Story: Liquidity

Earnings History and Estimates for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Great West Life Assurance Co. Can Decreases Stake in SBA Communications Co.
Great West Life Assurance Co. Can Decreases Stake in SBA Communications Co.
Great West Life Assurance Co. Can Acquires 59,099 Shares of Fortive Corp
Great West Life Assurance Co. Can Acquires 59,099 Shares of Fortive Corp
Sequent Asset Management LLC Sells 3,678 Shares of Wells Fargo & Co
Sequent Asset Management LLC Sells 3,678 Shares of Wells Fargo & Co
SINA  Shares Gap Down  After Analyst Downgrade
SINA Shares Gap Down After Analyst Downgrade
Babcock International Group  Rating Reiterated by Shore Capital
Babcock International Group Rating Reiterated by Shore Capital
Goldman Sachs Group Cuts Dixons Carphone  Price Target to GBX 148
Goldman Sachs Group Cuts Dixons Carphone Price Target to GBX 148


© 2006-2019 Ticker Report